Trial Profile
Effects of Oral Iron Supplementation Before vs. at Time of Vaccination on Immune Response in Iron Deficient Kenyan Women
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Feb 2024
Price :
$35
*
At a glance
- Drugs Ad26.COV2 S (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Iron
- Indications COVID 2019 infections; Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; SARS-CoV-2 acute respiratory disease
- Focus Pharmacodynamics
- 23 Jan 2024 Planned End Date changed from 10 Jul 2024 to 30 Sep 2024.
- 23 Jan 2024 Planned primary completion date changed from 26 Mar 2024 to 30 Jun 2024.
- 16 Oct 2023 Status changed from not yet recruiting to recruiting.